Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3720237 | 0.82 | ALDH1A1 (0.47) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL3311685 | 0.80 | LMNA (0.41) | ALDH1A1TDP1CHEK1LMNAL3MBTL1 | |
| SCHEMBL16003394 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL30378305 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL3311194 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL13362035 | 0.78 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL30682408 | 0.76 | ALDH1A1 (0.47) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL22954599 | 0.75 | MTNR1A (0.43) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL23428444 | 0.75 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL31049787 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | ALDH1A1 649/4885CYP3A4 49/4885TSHR 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.